COMMUNIQUÉS West-GlobeNewswire

NOTICE IN RELATION TO WAIVER OF LOCK-UP RESTRICTION

27/12/2017 - 07:01

REGULATED INFORMATION GHENT, Belgium, 27 December 2017 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan Securities LLC and Jefferies [...]

NANOBIOTIX : FDA approves Nanobiotix's first Immuno-Oncology trial

26/12/2017 - 23:30

FDA APPROVES NANOBIOTIX'S FIRST IMMUNO-ONCOLOGY TRIAL: A PHASE I/II STUDY OF NBTXR3 ACTIVATED BY RADIATION THERAPY (SABR) FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER OR HEAD AND NECK SQUAMOUS CELL CARCINOMA CANCER [...]

NANOBIOTIX : La FDA donne son accord pour le lancement du premier essai d'Immuno Oncologie de Nanobiotix

26/12/2017 - 23:30

LA FDA DONNE SON ACCORD POUR LE LANCEMENT DU PREMIER ESSAI D'IMMUNO ONCOLOGIE DE NANOBIOTIX : UNE PHASE I/II AVEC NBTXR3 ACTIVE PAR RADIOTHERAPIE (SABR), CHEZ DES PATIENTS ATTEINTS DE CANCER DU POUMON NON A PETITES [...]

NANOBIOTIX : 2017 review and 2018 expected milestones

26/12/2017 - 23:27

Nanobiotix: 2017 review and 2018 expected milestones Paris, France and Cambridge, Massachusetts, USA, December 26, 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company [...]

NANOBIOTIX : revue de l'année 2017 et perspectives 2018

26/12/2017 - 23:27

Nanobiotix : revue de l'année 2017 et perspectives 2018 Paris, France et Cambridge, Massachusetts, USA, 26 décembre 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), société française pionnière en nanomédecine [...]

HTG Molecular Diagnostics Expands its Collaboration with Merck KGaA, Darmstadt, Germany

26/12/2017 - 22:01

Signs Master Collaboration Agreement for Assay Development and Manufacturing of Kits Supporting Biomarker Research Programs TUCSON, Ariz. and DARMSTADT, Germany, Dec. 26, 2017 (GLOBE NEWSWIRE) -- HTG Molecular [...]

UPDATE - Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC

26/12/2017 - 17:41

LOUISVILLE, Colo., Dec. 26, 2017 (GLOBE NEWSWIRE) -- Rezolute , Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies [...]

FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as Investigational Treatment for Prader-Willi Syndrome

26/12/2017 - 14:30

PHOENIX, Dec. 26, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY ), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s cannabidiol (CBD [...]

Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D., as President and Chief Executive Officer

26/12/2017 - 14:05

TUSTIN, Calif., Dec. 26, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM ) (NASDAQ: PPHMP ), a company committed to improving patient lives by manufacturing and delivering high quality biologics, [...]

Organovo Receives Orphan Designation From U.S. FDA for 3D Bioprinted Therapeutic Liver Tissue Treatment of Alpha-1 Antitrypsin Deficiency

26/12/2017 - 14:05

SAN DIEGO, Dec. 26, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO ) (“Organovo”) today announced that the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation for the Company’s [...]

India Globalization Capital to use Blockchain to Address Issues Specific to the Medical Cannabis Industry

26/12/2017 - 14:00

BETHESDA, Md., Dec. 26, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC), today announces that it will leverage its existing team of technology and healthcare experts to develop methods [...]

Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC

26/12/2017 - 14:00

LOUISVILLE, Colo., Dec. 26, 2017 (GLOBE NEWSWIRE) -- Rezolute , Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies [...]

Endonovo Therapeutics Acquires Assets of Electroceuticals Developer, Rio Grande Neurosciences, and Settles Lawsuit

26/12/2017 - 13:30

Endonovo to Fund All Currently Planned and Future Clinical Trials for Traumatic Brain Injury, Post-Concussion Syndrome, Stroke and Other Central Nervous System Disorders LOS ANGELES, CA, Dec. 26, 2017 (GLOBE NEWSWIRE [...]

FDA Grants Orphan Drug Designation to Aptose Biosciences for CG’806 in Acute Myeloid Leukemia

26/12/2017 - 13:30

SAN DIEGO and TORONTO, Dec. 26, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO ) (TSX: APS ) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CG’806 [...]

Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 Mutation

26/12/2017 - 13:30

- Ivosidenib Has Potential to be a First-in-Class Therapy for Patients with R/R AML and an IDH1 mutation - - Company Also Announces FDA Clearance of Investigational New Drug Application (IND) for AG-270 Targeting MTAP- [...]

Transactions in relation to share buyback program

26/12/2017 - 09:24

Acting under its share buyback authorization, the GN Store Nord board of directors initiated a share buyback program on May 4, 2017 in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

NANOBIOTIX : 2017 review and 2018 expected milestones

26/12/2017 - 08:50

Nanobiotix: 2017 review and 2018 expected milestones Paris, France and Cambridge, Massachusetts, USA, December 26, 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company [...]

NANOBIOTIX : revue de l'année 2017 et perspectives 2018

26/12/2017 - 08:50

Nanobiotix : revue de l'année 2017 et perspectives 2018 Paris, France et Cambridge, Massachusetts, USA, 26 décembre 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), société française pionnière en nanomédecine [...]

NANOBIOTIX : FDA approves Nanobiotix's first Immuno-Oncology trial

26/12/2017 - 08:16

FDA APPROVES NANOBIOTIX'S FIRST IMMUNO-ONCOLOGY TRIAL: A PHASE I/II STUDY OF NBTXR3 ACTIVATED BY RADIATION THERAPY (SABR) FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER OR HEAD AND NECK SQUAMOUS CELL CARCINOMA CANCER [...]